Trelegy is delivered via the innovative Ellipta inhaler that provides accurate dosing through its consistent dose delivery mechanism and is associated with less inhaler teaching time compared to other commonly used inhalers, the company said. Estimated COPD prevalence in India is over 100 million and accounts for over 9.5 per cent of the total deaths in India.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Cx6MwY5
via IFTTT
Home »
Healthcare/Biotech-Industry-Economic Times
» GSK launches once daily, single inhaler-triple therapy for COPD patients
0 comments:
Post a Comment